Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2023 | A Phase II single-arm study of obinutuzumab plus ibrutinib as frontline treatment for FL and MZL

Sameh Gaballa • 10 Dec 2023
ASH 2023
Follicular Lymphoma Lymphoma Marginal Zone Lymphoma Non-Hodgkin Lymphoma Antibodies BTK inhibitors Ibrutinib Obinutuzumab

Sameh Gaballa, MD, Moffitt Cancer Center, Tampa, FL, briefly discusses the results of a Phase II single-arm study of obinutuzumab and ibrutinib as frontline treatment for patients with follicular lymphoma (FL) or marginal zone lymphoma (MZL). The safety profile was favorable, and promising outcomes were observed, indicating that this combination therapy holds potential as a chemotherapy-free regimen for newly diagnosed patients. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Sameh Gaballa

2:38
A double step-up dosing approach to decrease toxicity of AZD0486, a novel CD19xCD3 bsAb for NHL
Sameh Gaballa • 10 Dec 2023

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals